Treatment that included early surgical procedures to open blocked arteries resulted in better blood flow to the heart than aggressive medical treatment alone in patients with both diabetes and heart disease, according to a study presented at the American Heart Association's Scientific Sessions 2010.
Previously, researchers in BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) found that over five years there were no fewer deaths and heart attacks in people who had medical treatment along with prompt vessel-opening surgery (revascularization) than in those who received only intensive treatment to manage blood sugar, blood pressure and cholesterol levels (with surgery performed later only if their condition worsened).
"Even though the main trial showed no difference in clinical outcomes, this study revealed that revascularization had a greater benefit in reducing the extent of ischemia (areas with reduced blood flow), which is often important in controlling symptoms," said Leslee J. Shaw, Ph.D., lead author of the study and professor of medicine at Emory University School of Medicine in Atlanta, Ga.
In the current sub-study of BARI 2D, 1,505 participants underwent an imaging procedure that located and measured areas of heart muscle receiving sufficient blood flow. One year into the trial, researchers found:
The results indicate the value of scanning patients with diabetes and heart disease who are being managed with medication and lifestyle interventions.
"The benefits of lifestyle and medication take several months, so scanning after a year can provide a barometer of how effective your treatment has been at reducing ischemia," Shaw said. "Because nerves can be damaged by high blood sugar levels, people with diabetes don't always get chest pain when blood flow is reduced. This test can show reductions in blood flow whether or not you have symptoms, and a normal test can be very reassuring."
The BARI 2D trial compared various treatment strategies for patients with both type 2 diabetes and heart disease.
More than 17 million adults in the United States have diabetes, which is one of the strongest risk factors for heart disease.
Co-authors are: Manuel Cerqueira, M.D.; Maria M. Brooks, Ph.D.; Veronica V. Sansing, M.S.; George A. Beller, M.D.; Rodica Pop-Busui, M.D.; Raymond Taillefer, M.D.; Bernard R. Chaitman, M.D.; Raymond J. Gibbons, M.D.; and Ami E. Iskandrian, M.D. Author disclosures are on the abstract. The National Heart, Lung, and Blood Institute funded the study.
Statements and conclusions of study authors that are presented at American Heart Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position. The association makes no representation or warranty as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at www.heart.org/corporatefunding.
Multimedia resources (animation, audio, video, and images) are available in our newsroom at Scientific Sessions 2010 - Multimedia. This will include audio interview clips with AHA experts offering perspective on news releases. Video clips with researchers will be added to this link after each embargo lifts.
Stay up to date on the latest news from American Heart Association scientific meetings, including Scientific Sessions 2010, by following us at www.twitter.com/heartnews. We will be tweeting from the conference using hashtag #AHA10News.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.